BIO : Analysis & Opinions

  1. Salix Gains on Destocking Initiatives, Gives 2-Year Outlook - ...

    December 17, 2014
    Salix (SLXP) expects to resolve its inventory situation a year ahead of schedule and now expects a FDA response on Xifaxan ...
  2. Zacks#1 Ranked Healthcare Mutual Funds - Best of Funds

    June 20, 2013
    In this article we share with you 5 top rated health mutual funds. Each has earned a Zacks #1 Rank (Strong Buy) as we expect ...
  3. Zacks#1 Ranked Fidelity Mutual Funds - Best of Funds

    June 18, 2013
    In this article the Zacks Investment Research team shares with you the 5 top rated Fidelity mutual funds. Each has earned ...
  4. Danaher Proves Even The Nimble Can Stumble

    May 14, 2013
    Danaher won't stay stuck for long.
  5. Pressure BioSciences (PBIO), One of the Most Undervalued Biotech ...

    November 29, 2012
    Pressure BioSciences (PBIO), One of the Most Undervalued Biotech Companies By Grant Zeng, CFA   Pressure BioSciences (PBIO) ...
  6. PBIO continues to move in a positive direction - Analyst Blog

    July 11, 2012
    Grant Zeng, CFA Another Favorable Financing For PBIO The Deal On July 3, 2012, Pressure BioSciences, Inc. (PBIO) announced ...
  7. Medicine Gets Personalized

    June 28, 2012
    With our population continuing to age and grow, innovation in the healthcare sector will need to move just as fast. One such ...
  8. Bio-Reference Labs Taking Advantage Of Esoteric Opportunities

    June 22, 2012
    The decision of whether to buy Bio-Reference really comes down to an investor's confidence in the growth prospects for the ...
  9. Strategic Collaboration Means Better Penetration in the Sample ...

    May 8, 2012
    Strategic Collaboration Means Better Penetration in the Sample Preparation Market Grant Zeng, CFA On May 7, 2012, Pressure ...
  10. Ruling Or Not, Healthcare Still Wins

    March 29, 2012
    The Affordable Care Act finally goes in front of the Supreme Court. However, the Justice’s ruling may not matter. Healthcare ...
  11. 2011 In Review – The Best-Performing Mutual Funds

    January 3, 2012
    We discuss the best-performing mutual funds in a disappointing year for many mutual fund investors.
  12. Neogen Is Almost Cheap

    December 30, 2011
    Neogen has to do more to validate this price.
  13. Corn Will Rise Despite Subsidy Woes

    July 11, 2011
    The decision to end ethanol subsidies could be seen as a game changer for the industry. However, many long-term fundamentals ...
  14. Immucor Passes Its Last Test

    July 5, 2011
    Immucor gets a fair price for its shareholders.
  15. Ethanol Wins The Battle, Not The War

    June 15, 2011
    The senate gave the U.S. ethanol subsidy a little new life this week. Which ethanol stocks win and lose?
  16. Novo Nordisk Still One Of The Best Around

    May 3, 2011
    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  17. MannKind And The FDA - Here We Go Again

    January 20, 2011
    MNKD got another FDA setback in its attempts to bring inhaled insulin to the market.
  18. The Curious And Complicated Case Of MannKind

    December 15, 2010
    MannKind is a classic high-risk high-reward biotech story.
  19. Merck Makes A Smart Buy

    December 3, 2010
    Merck is making an exciting bet on a possible diabetes breakthrough.
  20. Trick Or Treat For Biodel?

    October 21, 2010
    Will Biodel's upcoming PDUFA date give investors a treat or just leave a sour taste?
Trading Center